Advertisement
Table 3 Retrospective comparison in 11 patients
| New ID | Cancer | Number of SNVs | Number of CNVs | MASTER report | MTB report | ||||
|---|---|---|---|---|---|---|---|---|---|
| Gene | Drug | Number of results | Match | Match level | Drug support | ||||
| MASTER-01 | Breast cancer metastasis | 104 | 3410 | BRCA1/2 deletions | PARP inhibitors | 43 | Yes | B2 | 11.6% |
| RAF1, PDGFRA amplifications | Sorafenib | Yes | B3 | 4.6% | |||||
| FGF1 (T8N) | FGFR inhibitor | Yes | – | 2.3% | |||||
| MASTER-02 | Pancreatic adenocarcinoma | 49 | 1528 | KRAS (G12D) | – | 92 | – | – | – |
| MASTER-03 | Leiomyosarcoma of the retroperitoneum | 31 | 3181 | PTPRJ deletion | Pazopanib | 12 | No | – | – |
| CDK12 + BRCA2 deletions | Cisplatin | Yes | B2 | 50% | |||||
| MASTER-04 | Ovarian carcinoma | 98 | 3385 | TSC2 (R505X) | mTOR inhibitor | 56 | Yes | B2 | 12.5% |
| MASTER-05 | Myxoid liposarcoma | 11 | 72 | PIK3CA (C420R) + PTEN (R130G) | mTOR inhibitor | 75 | Yes | B2 | 9.3% |
| AKT inhibitor | Yes | B2 | 2.4% | ||||||
| PI3K inhibitor | Yes | B2 | 32% | ||||||
| MASTER-06 | Neuroendocrine tumor | 2703 | 2060 | MTOR (P2490L, G332R) | mTOR inhibitor | 89 | Yes | B2 | 16.8% |
| PTPN12 (S509 N, G523S) | Lapatinib, erlotinib, imatinib, desatinib | No | – | – | |||||
| KIT (A837T) | Imatinib, desatinib | Yes | B3 | 1.1% | |||||
| LCK (P74L) | Desatinib | No | – | – | |||||
| MASTER-07 | Neuroendocrine tumor | 645 | 941 | ERBB3 (V104 M), RAF1 (S259P), MTOR (E1485G) | mTOR inhibitor | 40 | Yes | A2 | 12.5% |
| MASTER-08 | Cholangiocarcinoma | 28 | 1001 | ERRFI1 (R199X) | Erlotinib | 17 | Yes | – | 0.58% |
| MASTER-09 | Clear cell sarcoma | 11 | 1 | NTRK3 (R116W) | Lestaurtinib, midostaurin | 3 | No | – | – |
| MASTER-10 | Histiocytic sarcoma | 7 | 5 | BRAF (F595 L) + HRAS (Q61R) | MEK inhibitor | 11 | Yes | B2 | 33.3% |
| sorafenib (multi TKi) | Yes | B3 | 5.5% | ||||||
| MASTER-11 | Pulmonary adenocarcinoma | 70 | 146 | EGFR (p.745-750del) | Erlotinib | 54 | Yes | B2 | 22.2% |
